{"schema_version":"secwatch.filing_event.v1","accession":"0001682852-24-000043","form_type":"8-K","ticker":"MRNA","cik":"0001682852","company_name":"Moderna, Inc.","filed_at":"2024-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.104583+00:00","generated_at":"2026-05-31T13:51:52.690433+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Moderna Q2 net loss $1.3B, EPS $(3.33); cuts 2024 product sales forecast to $3.0-3.5B","bullets":["Revenue $241M vs $344M YoY; net product sales $184M (-37%).","Revised FY2024 product sales guidance to $3.0-3.5B; cites low EU sales, deferrals, competitive US market.","RSV vaccine mRESVIA approved by FDA, shipping since July; EMA positive opinion.","Phase 3 data positive for combo flu+COVID and next-gen COVID vaccines; filings planned in 2024.","David Rubenstein joins Board Aug 5; Robert Langer and Stephen Berenson retire."],"urls":{"canonical":"https://secwatch.observer/filing/0001682852-24-000043","json":"https://secwatch.observer/filing/0001682852-24-000043.json","markdown":"https://secwatch.observer/filing/0001682852-24-000043.md","text":"https://secwatch.observer/filing/0001682852-24-000043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1682852/000168285224000043/0001682852-24-000043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1682852/000168285224000043/mrna-20240801.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:51:52.690433+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}